Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease

  • Susan M Catalano (Creator)
  • Owen Dando (Creator)
  • Mary E Hamby (Creator)
  • Nicholas J Izzo (Creator)
  • Colin Smith (Creator)
  • Tara Spires-Jones (Creator)
  • Marti Colom Cadena (Creator)
  • Jamie Toombs (Creator)
  • Elizabeth Margaret Simzer (Creator)
  • Jane Tulloch (Creator)
  • Rosemary Jackson (Creator)
  • James Catterson (Creator)
  • Jamie Rose (Creator)
  • Lora Waybright (Creator)
  • Anthony O Caggiano (Creator)
  • Caitlin Davies (Creator)
  • Monique Hooley (Creator)
  • Sophie Dunnett (Creator)
  • Robert Tempelaar (Creator)
  • Makis Tzioras (Creator)



Data from Colom-Cadena et al Published in Acta Neuropathologica in 2024. Abstract: Synapse loss correlates with cognitive decline in Alzheimer’s disease, and soluble oligomeric amyloid beta (Aβ) is implicated in synaptic dysfunction and loss. An important knowledge gap is the lack of understanding of how Aβ leads to synapse degeneration. In particular, there has been difficulty in determining whether there is a synaptic receptor that binds Aβ and mediates toxicity. While many candidates have been observed in model systems, their relevance to human AD brain remains unknown. This is in part due to methodological limitations preventing visualization of Aβ binding at individual synapses. To overcome this limitation, we combined two high resolution microscopy techniques: array tomography and Förster resonance energy transfer (FRET) to image over 1 million individual synaptic terminals in temporal cortex from AD (n=11) and control cases (n=9). Within presynapses and postsynaptic densities, oligomeric Aβ generates a FRET signal with transmembrane protein 97. Further, amyloid beta generates a FRET signal with cellular prion protein, and postsynaptic density 95 within postsynapses. Transmembrane protein 97 is also present in a higher proportion of postsynapses in Alzheimer’s brain compared to controls. We inhibited Aβ / transmembrane protein 97 interaction in a mouse model of amyloidopathy by treating with the allosteric modulator CT1812. CT1812 drug concentration correlated negatively with synaptic FRET signal between transmembrane protein 97 and Aβ. In human induced pluripotent stem cell derived neurons, transmembrane protein 97 is present in synapses and colocalizes with Aβ when neurons are challenged with human Alzheimer’s brain homogenate. Transcriptional changes are induced by Aβ including changes in genes involved in neurodegeneration and neuroinflammation. CT1812 treatment of these neurons caused changes in gene sets involved in synaptic function. These data support a role for transmembrane protein 97 in the synaptic binding of Aβ in human Alzheimer’s disease brain where it may mediate synaptotoxicity.
Date made available9 Jan 2024
PublisherEdinburgh DataShare

Cite this